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Abstract  Over  the  past  three  decades,  transcatheter  arterial  embolization  has  become  the
ﬁrst-line therapy  for  the  management  of  acute  nonvariceal  upper  gastrointestinal  bleeding
that is  refractory  to  endoscopic  hemostasis.  Advances  in  catheter-based  techniques  and  newer
embolic agents,  as  well  as  recognition  of  the  effectiveness  of  minimally  invasive  treatment
options, have  expanded  the  role  of  interventional  radiology  in  the  treatment  of  bleeding  for  a
variety of  indications.  Transcatheter  arterial  embolization  is  a  fast,  safe,  and  effective  mini-
mally invasive  alternative  to  surgery,  when  endoscopic  treatment  fails  to  control  acute  bleeding
from the  upper  gastrointestinal  tract.  This  article  describes  the  role  of  arterial  embolization
in the  management  of  acute  nonvariceal  upper  gastrointestinal  bleeding  and  summarizes  the
literature evidence  on  the  outcomes  of  endovascular  therapy  in  such  a  setting.© 2015  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.Upper  gastrointestinal  bleeding  (UGIB)  is  deﬁned  as  originating  in  the  distal  esophagus,
stomach,  and  duodenum  (proximal  to  the  ligament  of  Treitz).  The  most  common  cause  of
nonvariceal  UGIB  is  peptic  ulcer  disease.  Other  less  common  causes  include  benign  and
malignant  tumors,  ischemia,  gastritis,  arteriovenous  malformations  such  as  Dieulafoy’s
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esions,  Mallory-Weiss  tears,  trauma  and  iatrogenic  causes
1,2].  Effective  treatment  requires  timely  and  accurate
iagnosis  (location  and  etiology),  and  unlike  lower  gastroin-
estinal  bleeds,  most  patients  have  undergone  endoscopic
xamination  and  treatment  prior  to  their  referral  to  inter-
entional  radiology.  Of  the  small  group  of  patients  with
ailed  endoscopic  therapy,  some  are  treated  surgically  [3],
ut  increasingly,  the  majority  is  referred  for  embolotherapy
4].  Transcatheter  arterial  embolization  (TAE)  has  been  per-
ormed  for  at  least  three  decades  and  has  been  shown  to  be
ffective  at  controlling  hemorrhage  and  decreasing  mortal-
ty  [5—10].  Embolization  techniques  have  evolved  with  the
se  of  microcatheters  and  new  embolic  agents.  The  purpose
f  this  review  is  to  summarize  data  on  indications,  tech-
iques  and  outcomes  of  embolization  procedures  for  acute
onvariceal  UGIB.
auses of acute nonvariceal UGIB
everal  population-based  and  prospective  studies  support
eptic  ulcer  disease  (PUD)  being  the  most  common  cause  of
cute  UGIB  [11].  PUD  refers  to  either  gastric  or  duodenal
lcers,  but  under  a  broad  heading  of  ‘‘ulcers’’  some  inves-
igators  also  include  esophageal  ulcers.  Approximately  50%
f  all  cases  of  acute  UGIB  are  attributed  to  PUD  [11].
Another  recently  reported  trend  in  acute  UGIB  involves
yclooxygenase-2  inhibitors.  Cyclooxygenase-2  inhibitors,
nown  for  their  decreased  gastrointestinal  toxicity,  are
xtensively  used  for  both  their  anti-inﬂammatory  and
nalgesic  properties.  Population-based  studies  evidence
uggests  that  the  introduction  of  cyclooxygenase-2  inhibitors
ay  be  associated  with  an  overall  increased  nonsteroidal
nti-inﬂammatory  drug  use  and  UGIB  [12].  Gastrointestinal
emorrhage  can  certainly  be  facilitated  when  a  patient  has
n  endogenous  coagulopathic  state  or  is  taking  anticoagula-
ion  therapy.
Classically,  Mallory-Weiss  tears  are  mucosal  lacerations
t  the  gastroesophageal  junction  or  in  the  cardia  of  the
tomach  [13].  These  lesions  can  be  associated  with  repeated
etching  or  vomiting  and  are  another  important  cause
f  nonvariceal  UGIB.  It  is  estimated  that  5  to  15%  of
ll  cases  of  acute  UGIB  are  secondary  to  Mallory-Weiss
ears  [13,14].
Vascular  ectasias,  also  referred  to  as  ‘‘angiomas’’,
‘arteriovenous  malformations’’  and  ‘‘angiodysplasia’’,  are
nother  source  of  acute  and  chronic  nonvariceal  UGIB
15,16].  Vascular  ectasias  are  the  underlying  etiology  of
cute  UGIB  in  approximately  5  to  10%  of  cases  and  the
everity  of  bleeding  can  also  range  from  trivial  to  severe.
solated  vascular  ectasias  are  endoscopically  different  from
he  diffuse  linear  array  seen  in  gastric  antral  vascular  ecta-
ia,  also  referred  to  as  ‘‘watermelon  stomach’’  [17]. Gastric
ntral  vascular  ectasia  is  thought  to  be  a  distinct  clinical
ntity  from  portal  hypertensive  gastropathy.  Unlike  portal
ypertensive  gastropathy,  many  patients  with  gastric  antral
ascular  ectasia  do  not  have  portal  hypertension  [18].  The
xact  etiology  of  gastric  antral  vascular  ectasia  and  its  dif-
erences  from  portal  hypertensive  gastropathy  have  yet  to
e  fully  explained.
Dieulafoy’s  lesion  is  a  rare  etiology  in  acute  UGIB.
ieulafoy’s  lesions  are  difﬁcult  to  identify  endoscopically
t
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ecause  they  often  retract.  Their  histopathologic  descrip-
ion  is  a  ‘‘caliber-persistent  artery’’  in  the  submucosal
issue  [19]. These  lesions  are  responsible  for  less  than  5%
f  all  nonvariceal  UGIB.
Neoplasms,  both  malignant  and  benign,  are  another
nfrequent  cause  of  nonvariceal  UGIB  contributing  to  less
han  5%  of  all  UGIB  cases  [20].  Although  only  a small  fraction
f  UGIB  is  of  neoplastic  etiology,  this  may  be  the  only  pre-
enting  symptom  of  a  neoplasm,  which  should  be  included
n  the  differential  diagnosis.  The  lesion  can  be  a  primary
alignancy  of  the  esophagus,  stomach  or  duodenum.  They
ay  constitute  an  adenocarcinoma  (esophageal,  gastric,
r  duodenal),  squamous  cell  carcinoma  (esophagus),  lym-
homa  (gastric  or  duodenal)  or  a  gastrointestinal  stromal
ell  tumor.  Metastases,  such  as  those  from  the  colon,  lung,
nd  breast,  may  also  be  responsible  for  UGIB  [21]. Exam-
les  of  benign  neoplasms  that  can  lead  to  UGIB  include
arcinoid  tumors,  lipomas,  and  blue  rubber  bleb  nevus
yndrome  [22,23].
Other  rare  causes  of  nonvariceal  UGIB  should  also  be
onsidered  in  any  differential  diagnosis.  For  example,  aor-
oenteric  ﬁstula  must  be  considered  in  patients  with  a
istory  of  intra-abdominal  vascular  surgery,  such  as  an
bdominal  aortic  aneurysm  repair  [24]. Hemobilia  is  another
are  cause  of  UGIB  that  should  be  considered  in  the  set-
ing  of  recent  hepatobiliary  tree  instrumentation,  such  as
ith  endoscopic  retrograde  cholangiopancreatography  or
aparoscopic  cholecystectomy.  Bile  duct  and  hepatic  artery
njuries  are  possible  complications  of  these  procedures,  and
atients  can  ultimately  present  with  signs  of  UGIB  [25].  In
atients  with  chronic  pancreatitis  who  present  with  acute
GIB,  hemosuccus  pancreaticus  should  also  be  excluded.
lthough  it  is  an  uncommon  cause  of  UGIB  overall,  bleed-
ng  in  these  patients  can  be  secondary  to  a  pseudoaneurysm
n  peripancreatic  blood  vessels  as  a complication  of  pancre-
tic  pseudocysts  [26].  Finally,  iatrogenic  injuries  secondary
o  biopsies  or  endoscopic  procedures,  such  as  percuta-
eous  endoscopic  gastrostomy  tube  placement,  are  also  rare
ut  documented  causes  of  nonvariceal  UGIB  [26,27].  The
ain  causes  of  acute  nonvariceal  UGIB  are  summarized  in
able  1.
ascular anatomy of the stomach and
uodenum
he  vascular  supply  to  the  stomach  and  duodenum  is  quite
ich,  with  avid  redundant  supply.  This  can  make  successful
mbolization  more  challenging;  however,  it  decreases  the
ncidence  of  post-embolization  ischemia  [28].  The  likelihood
f  successful  embolization  reﬂects  prior  knowledge  of  the
ocation  of  the  bleed.  The  left  gastric  artery  (LGA)  runs  along
he  lesser  curve  of  the  stomach  and  supplies  the  stomach
nd  distal  esophagus.  The  LGA  is  most  often  the  ﬁrst  branch
f  the  celiac  trunk  (90%)  but  may  arise  directly  from  the
orta,  as  a  lienogastric  trunk,  or  hepatogastric  trunk  [29].  It
nastomoses  with  the  right  gastric  artery  (RGA).  Small  dis-
al  branches  anastomose  with  short  gastric  arteries  (from
he  splenic  artery)  and  the  left  inferior  phrenic  artery.  The
GA  most  often  originates  from  the  proper,  left,  or  middle
epatic  artery  but  may  also  arise  from  the  gastroduodenal
Embolization  for  arterial  upper  gastrointestinal  bleeding  733
Table  1  Causes  of  acute  upper  gastrointestinal
bleeding.
Etiologies  Percentage
Gastric  and  duodenal  ulcers  35
Variceal  bleeding  25
Acute  gastroduodenal  erosions  15
Esophagitis  10
Mallory-Weiss  tears  5
Esophageal  or  gastric  tumors 5
Rare  causes 5
Vascular  malformations  (angioma,
ectasia)
Dieulafoy’s  lesion
Aortoenteric  ﬁstula
Wirsungorrhagia
Hemobilia
Figure 1. Dual vascular supply anatomy of the stomach and duo-
denum. CHA: common hepatic artery; PHA: proper hepatic artery;
SMA: superior mesenteric artery; SPA: splenic artery; GDA: gastro-
duodenal artery; RGA: right gastric artery; LGA: left gastric artery;
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artery  (GDA)  or  the  right  hepatic  artery  (RHA).  It  is  typi-
cally  a  small  vessel  that  runs  in  the  gastrohepatic  ligament
and  supplies  the  distal  lesser  curve  of  the  stomach  and
the  pylorus.  The  greater  curvature  of  the  stomach  is  sup-
plied  by  the  gastroepiploic  arcade  (GEA)  that  courses  along
the  greater  curvature  of  the  stomach  and  is  supplied  by
the  right  gastroepiploic  artery  (RGEA),  the  terminal  branch
of  the  GDA,  and  the  left  gastroepiploic  artery  (LGEA),  a
branch  of  the  distal  spenic  artery  (SPA).  A  complete  arcade
(rather  than  incomplete  or  weak)  is  present  in  about  65%  of
patients.  The  duodenum  is  supplied  by  the  pancreaticoduo-
denal  arcade,  supplied  by  superior  and  inferior,  posterior
and  anterior  pancreaticoduodenal  arteries,  branches  of  the
GDA  and  superior  mesenteric  artery  (SMA),  respectively.  The
GDA  arises  from  the  common  hepatic  artery  in  a  large  major-
ity  of  patients,  but  may  also  arise  from  the  RHA,  a  replaced
RHA  branch  of  the  SMA,  or  directly  from  the  celiac  axis.  The
vascular  dual  supply  anatomy  of  the  stomach  and  duodenum
is  summarized  in  Fig.  1.
Indications for angiography
TAE  has  become  a  useful  diagnostic  and  therapeutic  tool  in
selected  populations  (5—10).  The  typical  candidate  patient
presents  with  massive  bleeding  (transfusion  requirement  of
at  least  4  units  of  blood  per  24  h)  or  hemodynamic  instability
(hypotension  with  systolic  pressure  less  than  100  mmHg  and
heart  rate  of  100/min  or  clinical  shock  secondary  to  blood
loss),  who  have  failed  to  respond  to  conservative  medi-
cal  therapy  consisting  of  volume  replacement,  antacids,  H2
receptor  blocking  agents,  or  proton  pump  inhibitors,  and
have  failed  at  least  one,  and  sometimes  two,  attempts
for  endoscopic  intervention  to  control  the  bleeding  [30].
Low  risk  patients  at  that  point  are  offered  the  option
of  surgical  intervention,  whereas  high-risk  individuals  are
directed  towards  TAE.  Finally,  endovascular  treatment  can
be  used  after  open  intervention  has  failed  and  the  bleeding
recurs.
T
I
aEA: gastroepiploic arcade; ASPD: antero-superior pancreaticoduo-
enal artery; PSPD: postero-superior pancreaticoduodenal artery.
ngiography procedure
iming of angiography
ndoscopy  is  performed  before  angiography.  Performance  of
ngiography  before  endoscopy  leads  to  an  unacceptably  high
requency  of  unnecessary  angiography.  Endoscopic  diagnosis
nd  therapy  can  render  angiography  unnecessary.  Endoscopy
lso  helps  in  planning  the  timing  and  approach  of  angiogra-
hy.  For  example,  inability  to  determine  the  cause  of  bleed-
ng  at  endoscopy  because  of  severe  bleeding  should  prompt
rgent  angiography.  Even  endoscopic  localization  of  the
leeding  site  without  determination  of  the  cause  helps  guide
hich  artery  to  cannulate  ﬁrst  at  angiography  [31]. Nega-
ive  endoscopic  information,  such  as  excluding  esophageal
leeding,  is  valuable  to  the  angiographer.  On  the  other  hand,
alsh  et  al.  [32]  and  Loffroy  et  al.  [30]  found  longer  time  to
ngiography  to  be  predictor  of  early  rebleeding  after  TAE.
hey  concluded  that  every  effort  should  be  made  to  perform
ngiography  with  embolization  early  after  bleeding  onset.
hus,  the  ability  to  achieve  bleeding  control  in  critically  ill
atients  seems  to  depend  chieﬂy  on  early  intervention.
Finally,  the  amount  of  bleeding  may  affect  treatment
trategy,  continued  active  bleeding  demands  for  emer-
ency  angiography  primarily  without  pre-procedural  testing.
efreyne  et  al.  [33]  and  Whitaker  and  Gregson  [34]  indepen-
ently  indicated  that  the  most  important  determinant  of  the
iming  of  angiography  may  be  the  ﬁndings  of  an  experienced
ndoscopist  when  faced  with  nontractable  bleeding.echnique of angiography
n  the  setting  of  UGIB,  the  source  for  hemorrhage  is  usu-
lly  identiﬁed  by  endoscopy.  Therefore,  angiography  is  most
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ften  performed  only  as  a  precursor  to  TAE  based  on  the
nown  vascular  supply  to  the  area  of  abnormality.  A  posi-
ive  examination  is  classically  described  as  extravasation  of
ontrast  into  the  bowel  lumen  or  false  aneurysm-like  lesion.
owever,  an  abnormal  blush  of  the  mucosal  surface  of  the
pper  gastrointestinal  tract  is  indicative  of  an  inﬂamma-
ory  process  (gastritis  or  duodenitis),  which,  if  correlated
ith  endoscopy  ﬁndings,  may  also  be  considered  a posi-
ive  angiographic  examination.  Angiography  in  the  setting
f  UGIB  is  positive  for  extravasation  or  abnormal  mucosal
lush  in  up  to  61%  of  cases  [35].  There  is  much  discussion
bout  the  necessity  of  diagnostic  studies  preceding  angiog-
aphy.  Computed  tomography  angiography  (CTA)  has  been
sed  accurately  (sensitivity  up  to  86%)  in  the  diagnosis  of
cute  gastrointestinal  bleeding  and  can  show  the  precise
ocation  and  etiology  of  bleeding,  thereby  directing  further
anagement  [35].  It  should  probably  be  performed  prior
o  any  invasive  procedure  in  the  absence  of  hemodynamic
nstability,  even  if  its  use  is  less  important  than  for  lower  gas-
rointestinal  bleeding  since  endoscopic  localization  of  the
leeding  site  is  the  rule  in  most  cases  at  the  upper  tract,
elping  guidance  for  TAE,  even  in  the  absence  of  extravasa-
ion.
By  the  time  a  patient  with  UGIB  reaches  the  interven-
ional  suite,  he  should  be  ﬂuid-resuscitated,  hemodynam-
cally  stable  and  have  any  coagulopathy  corrected.  Blood
roducts  such  as  fresh  frozen  plasma,  platelets,  or  packed
ed  blood  cells  may  also  be  given  intraprocedurally.  It  is
esirable  to  correct  any  coagulopathy  before  embolization,
ecause  achieving  hemostasis  depends  on  technically  suc-
essful  embolization  as  well  as  the  patient’s  ability  to  clot
roperly.  However,  in  case  of  acute  bleeding,  an  arteriog-
aphy  with  embolization  should  be  promptly  performed  and
oon  followed  by  coagulopathy  correction.  A  transfemoral
pproach  is  mostly  used  and  involves  placement  of  a  5-
rench  sheath  in  the  common  femoral  artery.  A  variety  of
ntroducers  and  selective  catheters  with  a  smaller  caliber
an  be  used  to  cannulate  the  celiac  artery  and  obtain  access
o  common  hepatic  artery.  For  selective  catheterization  via
he  femoral  route,  the  most  widely  used  catheter  conﬁg-
rations  are  the  cobra,  hook,  and  short-  and  long-curve
idewinder  with  a  diameter  of  4-French.  Once  access  is
ecured,  arteriogram  is  performed  to  delineate  the  anatomy
nd  identify  contrast  extravasation.  Selective  catheteriza-
ion  for  UGIB  includes  the  celiac  and  superior  mesenteric
rteries.  The  initial  artery  catheterized  is  the  one  most  sus-
ected  of  bleeding  based  on  prior  imaging  or  endoscopy,
hich  is  of  course  the  celiac  for  UGIB.  If  no  extravasa-
ion  is  seen,  then  superselective  angiography  is  advised,
epending  on  endoscopic  ﬁndings  that  offer  information  on
he  likely  location  of  the  bleeding  source:  superselective
atheterization  of  the  GDA,  the  LGA,  or  the  splenic  artery
ay  be  performed.  A  microcatheter  is  always  necessary
or  a  distal  and  superselective  approach  to  the  bleeding  as
ell  as  for  avoiding  the  spasm  caused  by  catethers  with
 4-French  or  5-French  caliber.  Longer  injection  durations
r  use  of  carbon  dioxide  for  contrast  medium  can  also
mprove  sensitivity  for  small  bleeds.  Arteriography  after
uperselective  cannulation  may  reveal  extravasation  that
ould  have  been  missed  during  contrast  injection  in  the
ain  hepatic  artery.  When  a  dual  supply  of  the  bleed-
ng  area  is  suspected,  both  arterial  sources  need  to  be
t
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mbolized  to  assure  that  all  the  inﬂow  ceases.  This  is  the
ypical  case  of  bleeding  secondary  to  an  ulcer  that  erodes
nto  the  gastroduodenal  artery;  embolization  in  this  case
eeds  to  start  distally  to  prevent  persistent  ‘‘back-door’’
emorrhage  from  the  right  gastroepiploic  and  superior  pan-
reaticoduodenal  arteries,  and  proceed  in  the  proximal  side
f  the  erosion.
rovocative angiography
e  do  not  believe  there  is  enough  data  to  provide  deﬁnitive
uidelines  to  perform  provocative  mesenteric  angiogra-
hy  or  pharmacoangiography.  Furthermore,  this  technique
s  mainly  used  to  provoke  lower  GI  bleeding,  which  is
ore  challenging  than  UGIB.  Indeed,  contrary  to  lower  GI
leeding,  almost  all  upper  gastrointestinal  bleeders  have
ndergone  endoscopy  in  an  attempt  to  identify,  localize
nd  treat  the  source  of  bleeding.  Several  prior  studies
ave  shown  that  empiric  embolization  based  on  endoscopic
ndings,  in  the  absence  of  contrast  extravasation,  can  be
erformed  safely  and  successfully  [36,37]. So  the  absence
f  angiographic  extravasation  is  less  problematic  at  the
evel  of  the  upper  gastrointestinal  tract  and  does  not  pre-
ent  from  embolizing  the  artery  that  supplies  the  bleeding
ite.
However,  this  technique  can  be  applied  in  situations
here  conventional  angiography  is  nondiagnostic.  The  addi-
ion  of  pharmacologic  agents  to  standard  angiographic
rotocols  in  order  to  increase  the  diagnostic  yield  has
een  reported  in  case  reports  and  small  series.  Provocative
esenteric  angiography  is  the  use  of  thrombolytic,  vasodi-
ating,  and  anticoagulation  medications  to  elicit  active
leeding  from  a  source  that  may  have  recently  ceased  hem-
rrhaging.  Unfortunately  the  available  literature  on  this
opic  is  limited.  Koval  et  al.  [38]  doubled  the  rate  of  extrava-
ations  visualized  by  angiography  from  32  to  65%  with  the
ntroduction  of  pharmacologic  angiography.  Malden  et  al.
39]  and  Ryan  et  al.  [40]  separately  showed  a  provoked
leeding  rate  of  nearly  40%  when  previous  angiograms  had
een  normal  with  a  minimal  complication  rate.  Although
easonably  successful  and  without  any  reported  major  hem-
rrhagic  complications,  provocative  mesenteric  angiography
s  not  a  commonly  used  examination.  The  precise  reasons
or  this  are  unknown  but  likely  relate  to  fear  of  poten-
ial  uncontrollable  hemorrhagic  complications  and  lack  of
amiliarity  with  this  procedure  by  referring  clinicians  and
nterventional  radiologists.  Both  of  these  are  likely  a  reﬂec-
ion  of  the  sparse  data  supporting  provocative  mesenteric
ngiography  in  the  literature.
Basically,  provocative  angiography  may  increase  the
iagnostic  ability  when  a normal  angiogram  is  encountered
or  nonvariceal  UGIB.  But  several  procedure-related  factors
ay  affect  the  diagnostic  yield  of  provocative  studies;
hese  include  timing  of  the  procedure,  the  type  and  dosage
f  provocative  medications,  and  the  expertise  of  the  opera-
ors.  The  types  of  pharmacological  provocation  reported  in
he  literature  have  been  variable  [41—45].  Based  on  these
ata,  an  idealized  protocol  could  include  intra-arterial
olazoline  at  a dose  of  25  mg,  intra-arterial  heparin  at  a
ose  targeted  to  double  the  patient’s  baseline  activated
lotting  time,  and  intra-arterial  urokinase  in  aliquots  of
50,000  U  given  over  15  min  and  monitored  by  diagnostic
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angiography.  Endpoints  are  either  hemorrhage  or  a  total  of
1,000,000  U  of  urokinase  over  an  interval  of  approximately
1  hour.  However,  it  should  be  emphasized  that  the  speciﬁc
agents  and  their  total  doses  in  literature  are  largely  arbi-
trary.  Currently,  provocative  angiography  is  rarely  needed
for  the  diagnosis  of  GI  bleeding  and  only  limited  reports
for  use  in  difﬁcult  and  recurring  nonvariceal  UGIB  have
shown  to  be  beneﬁcial.  We  believe  that  further  prospective
studies  are  required  to  provide  a  better  understanding
of  optimal  patient  selection  and  optimal  pharmacological
provocation.  Only  with  these  kinds  of  data  can  provocative
gastrointestinal  bleeding  studies  be  appropriately  placed
in  a  diagnostic  algorithm  for  evaluation  of  patients  with
gastrointestinal  hemorrhage  of  obscure  origin.
Embolization procedure
Over  the  past  three  decades,  angiographic  interventions
have  shifted  from  playing  a  purely  diagnostic  role  to  being  a
major  therapeutic  option  in  the  management  of  nonvariceal
UGIB.  Transcatheter  intervention  to  control  gastrointestinal
bleeding  takes  two  forms:  the  infusion  of  a  vasoconstrict-
ing  medication  and  the  mechanical  occlusion  of  the  arterial
supply  responsible  for  the  hemorrhage.
Intra-arterial vasopressin infusion
Selective  infusion  of  intra-arterial  vasoconstrictors  was
one  of  the  ﬁrst  angiographic  treatments  for  gastrointesti-
nal  bleeding.  Vasopressin,  a  posterior  pituitary  hormone,
elicits  smooth  muscle  contraction  in  the  mesenteric  bed,
thereby  decreasing  the  perfusion  pressure  to  the  bowel  and
potentially  resulting  in  thrombosis  of  the  bleeding  site.  Vaso-
pressin  infusion  is  easy  to  perform,  most  often  by  placing
a  5-French  diagnostic  catheter  into  the  artery  most  sus-
pected  of  bleeding  [46].  Vasopressin  is  then  infused  at  a
rate  of  0.2  to  0.4  U/min  until  successful  control  of  bleeding
is  observed  on  angiography.  Then,  the  mesenteric  intra-
arterial  infusion  is  continued  for  12—48  hours.  Vasopressin
infusion  has  lost  favour  for  two  main  reasons:  necessary
catheterization  times  can  require  several  days  and,  more
importantly,  the  emergence  of  embolotherapy.  For  nonva-
riceal  UGIB,  the  offending  arteries  were  easily  accessible
even  with  large  and  crude  catheter  systems  and  embolic
agents  of  the  past.  In  addition,  given  the  rich  arterial  collat-
eral  network  and  proximal  site  of  embolotherapy,  ischemia
was  not  thought  to  be  problematic.  Given  that  embolother-
apy  replaced  vasopressin  infusion  early  in  the  treatment  of
UGIB,  there  is  little  recent  data  on  the  use  of  this  technique.
In  addition,  much  of  the  data  include  treatment  of  variceal
bleeding.  A  review  of  four  of  the  recent  studies  consisting  of
267  patients  demonstrated  an  initial  70  to  80%  success  rate.
They  observed  approximately  20%  rate  of  rebleeding  with
hemorrhage  refractory  to  infusion  in  up  to  40%  of  patients
[47,48].  Failures  of  vasopressin  are  thought  to  be  due  to
the  rich  collateral  supply  to  the  upper  gastrointestinal  tract
and  the  inability  to  treat  potential  collateral  supply  path-
ways  to  the  bleeding  site,  but  this  is  unproven.  Finally,  the
use  of  vasopressin  in  the  treatment  of  nonvariceal  UGIB
is  empiric  as  there  is  no  substantial  data  to  support  its
use  [48].
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echnique
ecause  of  the  high  rebleeding  rate  with  infusion  therapy,
ther  angiographic  interventions  were  developed  to  treat
onvariceal  UGIB.  As  is  true  of  most  other  minimally  invasive
nd  image-guided  interventions,  embolotherapy  has  sup-
lanted  surgery  in  most  centers  as  the  treatment  of  choice
or  endoscopy-refractory  UGIB.  This  method  is  associated
ith  an  initial  bleeding  control  rate  of  89—98%.  Clinical
uccess  rates  rang  from  52—98%  with  most  reports  show-
ng  success  rates  of  70—80%  [30,33,36,49,50]. The  role  of
AE  is  to  selectively  reduce  blood  supply  at  the  source  of
leeding  while  maintaining  enough  collateral  blood  ﬂow  to
aintain  intestinal  viability.  Typically,  in  cases  of  active
emorrhage  with  extravasation  of  contrast,  the  bleeding
essel  is  identiﬁed  by  superselective  catheterization  using
 microcatheter  and  embolized  with  microcoils,  particles
r  glue  if  arterial  ﬂow  is  not  blocked  by  the  microcatheter
Fig.  2).  Superselection  and  embolization  of  short  segments
f  visceral  arteries  can  be  performed  with  newer  advances
n  hydrophilic  steerable  wires,  microcatheters  and  embolic
gents.  Coaxial  systems  allow  2  to  3-French  catheters  to
ass  through  larger  primary  catheters  to  allow  access  to  dis-
al  arterial  branches.  In  general,  bleeding  in  the  esophagus
nd  fundus  of  the  stomach  is  treated  by  embolization  of
he  LGA  (Figs.  3  and  4).  Bleeding  in  the  body  and  antrum
f  the  stomach  may  be  controlled  by  embolization  of  either
he  gastroepiploic,  right  gastric  or  gastroduodenal  arteries
epending  on  the  source  of  bleeding.
lind or empiric embolization
lind  embolization  is  controversial.  Because  massive  bleed-
ng  is  often  intermittent,  most  groups  have  adopted  a  policy
o  embolize  on  the  basis  of  endoscopic  ﬁndings  even  in
ituations  that  no  extravasation  is  seen  angiographically.
n  the  series  from  Aina  et  al.  [36],  Loffroy  et  al.  [30],
nd  Padia  et  al.  [37]  there  was  no  difference  of  outcome
etween  patients  who  underwent  blind  embolization  and
hose  who  underwent  embolization  after  a  bleeding  site
ad  been  demonstrated  angiographically.  Other  researchers
lso  advocate  the  practice  of  endoscopy-directed  blind
mbolization  [32,33]. Based  on  the  ﬁndings  from  the  lit-
rature  and  our  own  experience,  we  believe  that  blind
mbolization  is  appropriate.  The  GDA  should  be  embolized
sing  the  ‘‘sandwich  technique’’,  in  which  both  ends  of  the
rtery  are  ﬁlled  with  coils  to  avoid  retrograde  bleeding  from
he  superior  mesenteric  circulation  (Fig.  5).  If  there  is  suspi-
ion  that  smaller  muscular  branches  terminating  to  a  clip  are
he  culprits,  then  those  should  be  embolized  with  any  of  the
aterials  available.  The  ‘‘back-door’’  from  the  SMA  has  to
e  checked  angiographically  after  embolization  of  the  GDA
o  make  sure  there  is  no  retrograde  ﬁlling  of  the  bleeding
ite  (Fig.  6).
hoice of embolic agent
any  embolization  agents  have  been  used  success-
ully:  coils,  particulate  material  such  as  resorbable
elatin  sponge,  and  nonresorbable  polyvinyl  alcohol  (PVA)
r  tris-acryl  gelatin  particles.  Liquids  such  as  N-butyl
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Figure 2. Arteriogram images of bleeding from a bulbar duodenal ulcer in a 76-year-old man: a, b: arteriogram showing contrast medium
extravasated from a slender branch of the gastroduodenal artery into the duodenum (arrows); c, d: after microcatheterization, selective
glue embolization (radiopaque because of associated lipiodol (arrow)) preserving the gastroduodenal artery ensured control of the bleeding,
with no early or late recurrences.
Figure 3. Bleeding Dieulafoy’s lesion in an 87-year-old man: a, b: extravasation of contrast medium from the left gastric artery at the
celiac trunk and superselective angiography indicates continuing bleeding (arrows): c: after arterial microcatheterization, bleeding was
controlled after embolization of the left gastric artery using a Glubran® 2/lipidol mixture (1:3) (arrows).
Figure 4. Acute esophageal bleeding from the cardia in a 45-year-old man with hypovolemic shock: a: endoscopic view showing a cir-
cumferential hemorrhagic esophagitis of the distal part and the cardia; b: angiography demonstrating small esophageal branches arising
from the LGA without extravasation; c: control after blind selective embolization with glue, guided by clips. The bleeding was stopped
immediately without recurrence.
Embolization  for  arterial  upper  gastrointestinal  bleeding  737
Figure 5. Typical sandwich embolization in a 73-year-old woman with bleeding from a postbulbar duodenal ulcer at endoscopy: a, b: global
and selective angiography before embolization: no evidence of active bleeding, c: coil embolization of the distal and proximal gastroduodenal
artery (with gelatine sponge in the arterial trunk), including the anterior and posterior superior pancreaticoduodenal arteries and the right
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cgastroepiploic artery, to prevent retrograde ﬂow (arrows). Bleeding
2-cyanoacrylate  (NBCA)  glue  (Glubran®,  GEM,  Viareggio,
Italy)  or  ethylene-vinyl  alcohol  copolymer  (Onyx®,  Micro
Therapeutics,  Inc.,  Irvine,  CA,  USA)  are  less  popularly  used
[30,33,36,49,51].  The  choice  of  the  best  embolic  agent  is
still  debatable.  Embolotherapy  in  these  emergency  patients
has  to  be  fast,  easy  to  perform  and  effective.  Success  is
achievable  with  different  materials  in  experienced  interven-
tional  radiologist’s  hands.
Coils  alone  inserted  in  the  GDA  or  superselectively  in  the
pancreaticoduodenal  arteries  have  been  used  with  success
a
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Figure 6. Images of bleeding from a duodenal ulcer in a 68-year-old m
showing bowel hyperhemia; b: glue embolization of the GDA after protec
c: check control of the SMA showing ‘‘back-door’’ bleeding from a proxi
d: results after superselective embolization with Glubran® 2-cyanoacrylaped and no ischemic complications were reported.
y  several  investigators  [33,50,52].  When  used  in  the  set-
ing  of  UGIB,  coils  are  usually  used  to  occlude  or  reduce
ow  into  a  major  vessel,  which  can  also  be  treated  at  a
ore  distal  level  with  a  particulate  agent  (usually  gelatin
ponge)  to  aid  in  hemostasis.  The  main  advantages  of  using
oils  are  that  they  can  be  delivered  in  a  very  precise  fashion
nd  carry  low  risk  of  infarction  because  of  the  preserva-
ion  of  the  distal  microvasculature.  Coils  and  microcoils  of
ifferent  size  and  length  can  be  used.  They  may  have  throm-
ogenic  ﬁbers  to  facilitate  occlusion  of  the  vessel,  and  they
an: a: angiography before embolization, guided by metallic clips,
tion of the RGEA with coils to avoid distal embolization of the GEA;
mal jejunal branch with extravasation at the initial bleeding site;
te glue, without rebleeding.
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ay  offer  the  option  of  detachability  and  retrievability.  The
ain  drawback  is  that  they  are  permanent  and  may  pre-
lude  re-accessing  the  vessel  in  the  future  should  it  prove
ecessary.  Another  disadvantage  is  that  coil  application  is
ependent  upon  vessel  diameter  and  intrinsic  blood  clotting.
hat  is  probably  why  Aina  et  al.  [36]  and  Loffroy  et  al.  [30]
howed  an  association  between  the  use  of  coils  alone  and
he  incidence  of  bleeding  recurrence,  especially  in  patients
ith  coagulopathy.  The  advantages  of  use  of  PVA  or  gelatin
ponge  in  association  with  coils  when  choosing  a  strategy  for
his  subgroup  of  patients  cannot  be  over  stressed.
Gelatin  sponge  is  the  main  temporary  embolic  agent  used
orldwide.  It  has  the  advantage  that  after  resorption,  ﬂow
ill  be  restored  weeks  after  embolization.  Furthermore,  it
s  readily  available,  cheap,  and  unlikely  to  cause  ischemia.
he  disadvantages  are  that  it  requires  some  time  to  prepare
ppropriate-sized  particles,  and  the  pace  of  recanalization
s  unpredictable.  Lang  et  al.  [6]  compared  several  embolic
gents  in  a  series  of  57  patients.  They  reported  that  a
igh  rate  of  bleeding  recurrence  was  observed  when  gelatin
ponge  was  used  alone.  Similarly,  Encarnacion  et  al.  [8]
chieved  a  low  success  rate  (62%)  in  their  series,  which
ncluded  mostly  patients  embolized  with  gelatin  sponge
lone.  These  data  conﬁrm  that  the  use  of  gelatin  sponge  as
he  only  embolic  agent  guarantees  only  short-term  results
nd  should  probably  be  avoided.
Particles  such  as  PVA  particles  and  tris-acryl  gelatin
icrospheres  may  be  of  advantage  when  a  ﬂow-directed
trategy  is  favourable,  e.g.  when  diffuse  tumor  vasculariza-
ion  is  to  be  excluded  from  the  arterial  supply.  These  agents
ave  been  used  successfully  in  treating  gastrointestinal  hem-
rrhage,  usually  through  a  microcatheter  and  at  a  site  distal
o  major  vessels  [53].  Only  larger  particles  (>500  m)  should
e  used  to  decrease  the  risk  of  ischemia  from  normal  tissue
evascularization.
More  recently,  very  good  results  have  also  been  reported
ith  NBCA  [54—57].  Toyoda  et  al.  [56]  reported  that  the
ime  required  for  TAE  using  NBCA  was  signiﬁcantly  lower
han  for  TAE  procedures  that  do  not  use  NBCA.  This  is  impor-
ant  especially  in  cases  of  massive  bleeding  that  require
rgent  hemostasis.  Indeed,  the  use  of  NBCA  glue  is  partic-
larly  of  interest  in  hemodynamically  unstable  patients  and
n  cases  of  underlying  coagulopathy.  A  number  of  institu-
ions  have  adopted  selective  embolization  using  glue  as  the
nly  embolic  agent  as  the  salvage  treatment  of  choice  in
GIB  cases.  However,  the  use  of  NBCA  glue  requires  training
nd  considerable  experience,  given  the  risk  of  bowel  infarc-
ion  and  glue  reﬂux  into  other  vessels.  Reﬂux  of  NBCA  may
lso  result  in  its  polymerization  to  the  catheter  tip.  This
it  of  NBCA  may  then  be  stripped  from  the  catheter  dur-
ng  catheter  retraction,  resulting  in  nontarget  embolization.
he  use  of  a  proper  technique,  including  prompt  removal  of
he  catheter  after  injection  as  well  as  aspiration  of  the  guide
atheter  after  microcatheter  removal,  can  signiﬁcantly
educe  this  risk  [58].  Another  drawback  is  the  potential  risk
f  bowel  stenosis  over  the  long-term.  Lang  [53]  found  a
5%  duodenal  stenosis  rate  in  a  study  of  28  patients  that
ere  followed  up  for  at  least  ﬁve  years  after  embolization
or  bleeding  duodenal  ulcers,  even  if  the  link  between  glue
mbolization  and  duodenal  stenosis  is  difﬁcult  to  evaluate.
Onyx® seems  to  have  great  potential  as  a  liquid  embolic
gent  in  embolotherapy  of  acute  UGIB.  Lenhart  et  al.  [51]
t
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nd  Urbano  et  al.  [59]  recently  reported  their  experience
ith  the  use  of  Onyx® in  such  a  setting.  Their  studies  rep-
esent  the  ﬁrst  series  to  date  reporting  results  on  arterial
mbolotherapy  with  Onyx® as  an  embolic  agent  in  the  gas-
rointestinal  tract.  The  success  rate  was  high  (81%)  and  the
omplication  rate  was  almost  nil.  The  main  advantages  of
nyx® are  its  nonadhesive  properties,  high  radiopacity,  and
ong  solidiﬁcation  periods.  These  properties  of  Onyx® com-
ared  to  acrylic  glues,  make  the  embolization  procedure
ore  controllable  and  predictable  [60]. However,  Onyx®
as  some  disadvantageous  characteristics.  First,  DMSO  can
ause  severe  vasospasm  if  injected  rapidly.  Secondly,  DMSO
s  volatile  and  is  excreted  via  respiration  and  sweat.  This
as  a  typical  smell  not  unlike  that  of  diabetic  ketoacidosis
nd  may  last  a  few  days.  The  patient  and  ward  staff  should
e  warned  to  expect  this.  Lastly,  the  use  of  Onyx® has  cost
mplications  as  it  is  much  more  expensive  than  alternative
mbolic  materials  and  requires  speciﬁc  DMSO-compatible
icrocatheters.  These  factors  explain  its  restricted  use  in
euroradiology  in  most  of  the  institutions  around  the  world.
In  some  situations,  speciﬁc  endovascular  techniques  may
e  useful  to  stop  bleeding  as  coil  packing  of  a  pseudoa-
eurysmal  sac  (Fig.  7)  or  implantation  of  a  covered  stent
Fig.  8),  in  order  to  preserve  the  patency  of  the  parent
essel.
Finally,  it  is  not  clear  if  careful  selection  of  the  embolic
gents  according  to  the  bleeding  vessel  may  play  a  role
n  a  successful  outcome.  It  would  be  worth  comparing  the
ifferent  embolic  agents  for  arterial  embolotherapy  in  the
astrointestinal  tract  in  a  prospective  randomized  multi-
enter  trial.  However,  data  from  the  literature  suggest  that
oils  probably  should  not  be  used  as  the  only  embolic  agent,
ut  rather  in  association  with  gelatin  sponge,  particles  or
lue  for  the  treatment  of  gastroduodenal  hemorrhage.  Fur-
hermore,  surgical  glue  should  probably  be  used  more  often,
specially  in  patients  with  coagulopathy,  because  it  provides
 better  and  faster  hemostasis  and  does  not  cause  ischemia.
arking with a metallic clip
riksson  et  al.  [61]  reported  a  series  of  10  patients  who  were
eferred  for  embolotherapy  after  failed  endoscopic  attempt
o  control  bleeding  from  acute  duodenal  ulcer.  In  order  to
uide  the  endovascular  treatment,  the  endoscopists  marked
he  site  of  bleed  with  clips  placed  at  the  junction  of  the
lcer  and  the  adjacent  normal  mucosa.  In  eight  patients
emostasis  was  achieved  after  embolization,  whereas  sur-
ical  intervention  was  necessary  in  the  other  two.  The
lips  accurately  guided  the  endovascular  intervention  in  six
atients  who  had  no  evidence  of  contrast  extravasation  at
he  time  of  angiography.  This  was  of  particular  importance  in
hree  patients;  in  two  the  culprit  vessel  was  a  supraduode-
al  artery  without  connection  to  the  GDA,  whereas  the  third
as  bleeding  from  erosion  into  the  inferior  pancreaticoduo-
enal  artery  that  was  arising  from  the  superior  mesenteric
rtery.  Marking  with  a  metallic  clip  can  assist  with  localiza-
ion  of  the  vessel  feeding  the  bleeding  ulcer  even  if  there
s  no  contrast  medium  extravasation  after  injection  with
he  catheter  in  the  common  hepatic  or  the  main  trunk  of
he  GDA.  This  is  also  important  when  the  bleeding  artery
rises  separately  from  the  proper  hepatic  artery  or  the
DA.  Superselective  angiography  guided  by  clip  position  has
Embolization  for  arterial  upper  gastrointestinal  bleeding  739
Figure 7. A 41-year-old woman presented three weeks after laparoscopic cholecystectomy with right upper abdominal pain and hemobilia:
a: computed axial tomography scan: round mass within the gallbladder fossa that shows contrast ﬁlling at the arterial phase (arrow), and
dilatation of the bile duct (arrowhead); b: selective hepatic arteriogram demonstrating pseudoaneurysm of the cystic artery stump; c: coil
ing te
ain a
oembolization of the aneurysmal sac across the neck using the pack
complete occlusion of the false aneurysm and preservation of the m
better  chances  to  demonstrate  the  extravasation,  making
blind  coil  placement  unnecessary,  increasing  the  efﬁcacy  of
the  procedure  and  reducing  the  risk  of  coil  misplacement
and  inadvertent  hepatic  embolization.  The  only  limitation
o
w
c
Figure 8. Wirsungorrhagia in a 72-year-old woman with acute pancrea
the splenic artery communicating with the wirsung duct which is opaciﬁe
of the middle part of the splenic artery partially thrombosed; d: results
of the lesion.chnique through a microcatheter; d: control angiography showing
nd distal hepatic artery.
f  this  technique  is  the  need  for  around  the  clock  availability
f  an  experienced  interventionalist  and  gastroenterologist,
hich  is  easy  to  achieve  only  in  high  volume  medical
enters.
titis: a, b: CT scan of the abdomen showing a pseudoaneurysm of
d at the arterial phase; c: angiography conﬁrms a pseudoaneurysm
 after implantation of a covered stent showing complete exclusion
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utcomes
rocedural and  clinical outcomes
n  a  review  by  Loffroy  et  al.  [49],  15  studies  (819  patients,
ean  age  65  years)  on  endovascular  management  of
ntractable  nonvariceal  UGIB  were  identiﬁed.  Endoscopy  had
een  performed  and  failed  in  99%  of  patients.  The  vast
ajority  of  patients  treated  endovascularly  in  the  series
ad  signiﬁcant  comorbidities  and  was  deemed  high  risk
or  operative  intervention.  Endovascular  embolization  was
uccessful  technically  in  93%  of  patients.  The  causes  for
ndovascular  technique  failure  were  as  follows:  difﬁcult
ascular  anatomy,  arterial  dissection,  vasospasm,  false  neg-
tively  read  angiogram,  multiple  bleedings,  and  tumorous
leeding.  A  variety  of  embolic  materials  were  used.  The
‘sandwich’’  technique  with  placement  of  embolic  material
t  both  sides  of  the  bleeding  vessel  was  utilized  in  most
eries,  in  order  to  minimize  the  chance  of  recurrent  bleed-
ng  due  to  rich  collaterals.  Active  extravasation  was  present
t  the  time  of  embolization  in  only  54%  of  patients.  Con-
equently,  46%  of  patients  underwent  blind  embolization,
uided  by  the  ﬁndings  of  endoscopy  or  placement  of  clips
round  the  area  of  the  bleeding  vessel.  In  most  cases,  gelatin
ponge  or  coils  were  then  used  for  embolization.  From  the
ubgroup  that  underwent  technically  successful  emboliza-
ion,  67%  of  patients  responded  well  clinically  with  cessation
f  bleeding.
Thirty-three  percent  of  patients  continued  to  bleed  but
lmost  half  of  them  responded  to  repeat  embolization.
inally,  20%  of  patients  underwent  open  surgical  interven-
ion  to  deﬁnitively  manage  the  bleeding  source.  Major  and
inor  embolization-related  complications  developed  in  9%
f  patients  and  included  access  site  complications,  dissec-
ion  of  the  target  vessel,  and  liver  and  spleen  infarction.
he  most  signiﬁcant  long-term  complication  was  duode-
al  stenosis  in  a  series  by  Lang  [53],  particularly  after
r
r
r
u
Table  2  Outcomes  in  main  published  series  of  angiographic  e
bleeding.
Reference,  year  Clinical
success  (%)
Rebleed
rate  (%)
Lang  [53],  1992  86  56  
Encarnacion  et  al.  [8],  1992  62  11  
Toyoda  et  al.  [56],  1996  80  23  
Walsh  et  al.  [32],  1999  52  52  
Schenker  et  al.  [73],  2001  58  29  
Defreyne  et  al.  [33],  2003  60  37  
Aina  et  al.  [36],  2001  73  23  
De  Wispelaere  et  al.  [74],  2002  64  36  
Ripoll  et  al.  [68],  2004  71  29  
Holme  et  al.  [9],  2006  65  28  
Loffroy  et  al.  [52],  2008  94  17  
Larssen  et  al.  [75],  2008  72  9  
Poultsides  et  al.  [76],  2008 51  47  
Loffroy  et  al.  [30],  2009 72  28  
Padia  et  al.  [37],  2009 44  66  
NA: not available.R.  Loffroy  et  al.
lue  embolization  of  terminal  muscular  branches  of  the
astroduodenal  artery  (25%).  Overall  30-day  mortality  was
8%.  The  causes  of  death  were  underlying  conditions  in
ost  cases.  Although  the  mortality  appears  to  be  as  high
s  in  some  surgical  series  for  emergent  open  repair  of
GIB,  one  should  keep  in  mind  that  the  patients  treated
ith  embolotherapy  had  been,  in  most  occasions,  turned
own  for  open  repair  due  to  signiﬁcant  comorbidities  and
dvanced  age.  A  closer  look  into  this  review  of  outcomes  and
he  individual  studies  underscores  a  few  important  points.
irst,  mortality  and  complication  rates  exhibited  wide  vari-
bility  among  series,  further  emphasizing  the  importance
f  individual  expertise  and  center  experience  in  outcomes.
econd,  the  presence  of  active  extravasation  and  super-
elective  embolization  does  not  necessarily  imply  better
hort-term  clinical  response,  a  phenomenon  that  may  be
xplained  by  the  intermittent  nature  of  the  gastrointestinal
leeding,  and  the  presence  of  bleeders  that  were  missed
ith  the  very  selective  embolotherapy.  Last,  only  20%  of
he  patients  who  initially  underwent  embolization  ﬁnally
eeded  surgical  intervention  to  control  recurrent  bleeding,
ndicating  that  embolotherapy  can  reduce  the  incidence  of
aparotomy  in  patients  presenting  with  acute  UGI  bleed-
ng.  Surgery  was  usually  performed  after  failure  of  second
ndoscopic  hemostasis  or  embolization  procedure  at  the  dis-
retion  of  the  gastroenterologists  or  surgeons.  Main  results
re  summarized  in  Table  2.
omplications
roin  hematomas  (3  to  17%)  and  contrast-related
omplications  (0.04  to  12.7%)  can  occur  with  the  same
requency  as  in  other  endovascular  procedures  [49].  Acute
enal  failure  may  occur  and  its  etiology  is  multifactorial,
elated  to  the  contrast  injection  in  the  context  of  hemor-
hage  and  volume  depletion.  Arterial  embolization  in  the
pper  gastrointestinal  tract  above  the  ligament  of  Treitz  is
mbolization  for  acute  nonvariceal  upper  gastrointestinal
ing Need  for
surgery  (%)
Complication
rate  (%)
30-day
mortality  (%)
2  16  4
17  17  45
13  NA  23
37  4  40
NA  10  33
26  20  30
16  5  35
21  0  46
16  0  26
35  0  25
14  6  21
30  8  17
21  26  21
12  10  27
21  5  20
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aEmbolization  for  arterial  upper  gastrointestinal  bleeding  
generally  considered  very  safe  because  of  the  rich  collateral
supply  to  the  stomach  and  duodenum.  However,  the  risk  of
signiﬁcant  ischemia  after  embolization  is  known  to  increase
in  patients  with  previous  surgery  within  the  same  area
[32]  or  with  embolic  agents  that  can  advance  far  into  the
vascular  bed  such  as  liquid  agents  (e.g.,  tissue  adhesives  as
cyanoacrylate)  or  very  small  particles  (e.g.,  gelatin  sponge
powder  or  calibrated  microspheres)  [32,34]. Although  cases
have  been  reported  at  the  acute  phase,  post-embolization
ischemia  usually  presents  as  duodenal  stenosis  at  the
chronic  phase.  Lang  [53]  reported  duodenal  stenosis  in
seven  of  28  patients  8  months  to  7  years  after  embolization
of  terminal  vessels,  mostly  when  tissue  adhesive  was  used.
In  this  series,  duodenal  stenosis  after  GDA  embolization
was  far  less  common  and  occurred  in  only  two  of  29
patients  who  underwent  more  proximal  GDA  occlusion.
The  high  incidence  of  stenosis  of  the  duodenum  attendant
upon  embolization  of  the  terminal  vessels  of  a  bleeding
site  is  thought  to  be  the  consequence  of  severe  hypoxia
and  resultant  avascular  necrosis.  Surgical  correction  of
the  stenosis  was  necessary  in  eight  patients  to  address
persistent  symptoms.  Another  patient  had  to  undergo
multiple  balloon  dilatations  for  duodenal  stenosis.  Balloon
dilatations  were  performed  in  one  additional  patient  after
surgical  resection  and  recurrent  symptoms  of  duodenal
obstruction.
Inadvertent  embolization  of  the  main  hepatic  artery  can
result  to  a  broad  spectrum  of  manifestations,  ranging  from  a
temporary  increase  in  the  liver  enzymes,  to  life-threatening
hepatic  failure,  the  latter  being  more  common  in  the  set-
ting  of  cirrhosis  and  associated  compromise  of  the  portal
vein  circulation.  Inadvertent  placement  of  coils  in  the  main
branches  of  the  celiac  axis  has  been  reported  (up  to  3.3%)
[49],  usually  in  keeping  with  technical  difﬁculty  or  coil
migration.  Given  the  rich  collateral  circulation,  however,
coils  in  the  left  gastric  or  splenic  artery  rarely  produce
organ-threatening  ischemia  [49].
Predictors of success and survival
Although  few  published  series  analyzed  factors  predicting
embolization  failure,  there  are  now  enough  data  on  fac-
tors  that  may  inﬂuence  the  outcome  of  patients  who  have
undergone  embolization  procedures  for  acute  UGIB  [49].
Among  clinical  predictors  of  rebleeding,  coagulopathy
has  been  shown  to  adversely  affect  the  success  rate  for
embolotherapy,  with  an  increase  in  the  odds  ratio  for  clin-
ical  failure,  which  ranges  from  2.9  to  19.6.  Consequently,
every  effort  should  be  made  to  correct  coagulopathy  before,
during,  and  after  intervention.
Other  clinical  variables  have  been  identiﬁed  as  predic-
tors  of  early  rebleeding  after  embolization.  Several  of  the
variables  that  were  studied  in  our  largest  series  such  as
coagulation  disorders,  a  longer  time  from  shock  onset  to
angiography,  a  larger  number  of  RBC  units  transfused  before
angiography,  and  having  ≥2  comorbid  conditions  were  found
to  be  associated  with  early  rebleeding  [30].  Thus,  the  abil-
ity  to  achieve  bleeding  control  in  critically  ill  patients  seems
to  depend  chieﬂy  on  early  intervention  and  severity  of  the
underlying  disease.  Previous  surgery  for  bleeding  is  also  a
well-documented  independent  predictor  of  poor  emboliza-
tion  outcome  [32].
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Clinical  signs  of  shock  and  active  bleeding  at  admis-
ion  are  known  risk  factors  for  rebleeding  after  endoscopic
herapy;  hence,  they  are  probably  risk  factors  for  early
ecurrence  after  embolization  as  well  [62,63].  Corticos-
eroid  use  is  more  often  encountered  in  inpatients  with
leeding  than  in  those  with  primary-referred  UGIB,  but  it
as  not  yet  been  reported  to  be  an  independent  risk  factor
or  rebleeding.
Factors  inﬂuencing  mortality  include  advanced  age,
rauma  or  sepsis,  recent  major  operation,  lung  or  liver
isease,  and  massive  blood  transfusions.  A  number  of  fac-
ors  have  been  identiﬁed  as  inﬂuencing  post-embolization
ortality.  One  of  the  most  important  and  frequently  encoun-
ered  is  the  absence  of  early  recurrent  bleeding.  A  strong
orrelation  has  been  seen  between  coagulopathy,  clinical
ailure,  and  mortality  after  embolization  [49].
opics of interest
mbolization versus surgery
o  date,  there  has  been  no  controlled  trial  that  com-
ared  angiographic  embolization  to  surgery  as  a  salvage
rocedure  for  failed  endoscopic  therapy.  The  wide  array
f  alternatives  for  the  treatment  of  UGIB  after  endoscopic
ailure  make  the  decision  of  when  to  resort  to  emergency
urgery  more  difﬁcult,  especially  in  patients  with  risk  fac-
ors  for  recurrent  bleeding  and  death  that  are  also  related
o  high  surgical  risk.  Lau  et  al.  [64], in  a  randomized
ontrolled  study,  showed  no  differences  in  bleeding  con-
rol  between  a  second  endoscopic  treatment  and  surgery
fter  initial  endoscopic  treatment  failure  for  bleeding  pep-
ic  ulcers.  During  endoscopy,  active  bleeding,  large  ulcer
ize,  location  of  ulcer  at  posterior  bulbar  duodenum,  and
esser  curve  are  identiﬁed  as  predictors  for  endoscopic  fail-
re  [49]. Embolotherapy  may  be  particularly  attractive  in
uch  a  setting  because  it  is  not  as  invasive  as  surgery  and  has
ew  complications.  Another  advantage  of  TAE  is  that  most  of
he  patients  with  recurrent  bleeding  after  initial  treatment
ith  surgery  or  TAE,  can  be  effectively  treated  with  TAE,
voiding  a  second  surgical  procedure.
Despite  the  retrospective,  observational  design  of  the
tudy  by  Ang  et  al.  [65],  the  authors  provide  important,  clin-
cally  relevant  data  that  advances  our  knowledge  in  how  we
hould  be  caring  for  patients  with  UGIB.  The  ﬁndings  in  this
tudy  appear  to  conﬁrm  previously  published  retrospective
ase  series  that  support  the  role  of  TAE  and  show  it  reduces
he  need  for  surgery,  has  a  low  complication  rate,  and  does
ot  increase  mortality  [66—69]. Indeed,  four  other  retro-
pective  studies  compared  the  two  techniques  and  showed
t  least  similar  efﬁcacy  in  terms  of  rate  of  rebleeding,
orbidity,  and  mortality,  whereas  there  was  a bias  of  selec-
ion  since  TAE  was  preferentially  used  for  high  surgical  risk
atients.  These  data  suggest  that  surgery  would  have  proba-
ly  been  catastrophic  in  this  patient  population  and  that  TAE
ffered  better  results  [70]. Ripoll  et  al.  [68]  retrospectively
nalyzed  the  outcome  of  70  patients  with  refractory  pep-
ic  ulcer  bleeding.  Thirty-one  patients  underwent  TAE,  and
9  patients  were  managed  with  surgery.  Although  patients
eceiving  TAE  were  10  years  older,  and  more  patients  had
eart  disease  and  coagulation  disorders,  the  incidence  of
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ecurrent  bleeding  (29%  versus  23%)  and  mortality  was  sim-
lar  (26%  versus  21%).  Another  retrospective  comparison
tudy  by  Eriksson  et  al.  [69]  included  40  patients  who  under-
ent  TAE  and  51  patients  who  underwent  surgery  after
ailed  endoscopic  therapy.  The  TAE  group  was  older  and  had
ore  comorbidity.  Thirty-day  mortality  was  lower  in  the  TAE
roup  (3%  versus  14%).  More  recently,  Venclauskas  et  al.
67]  compared  these  two  treatment  strategies.  Arterial
mbolization  was  performed  in  24  patients  and  open  surgery
n  50  patients  after  unsuccessful  endoscopic  therapy  for
leeding  duodenal  ulcers.  The  mean  age  and  acute  physiol-
gy  and  chronic  health  evaluation  II  score  were  signiﬁcantly
igher  in  the  embolization  group.  Only  mortality  in  high-
isk  patients  was  signiﬁcantly  lower  in  the  TAE  group  (23.1%
ersus  50%).  In  a  retrospective  comparative  study  by  Wong
t  al.  [15],  the  30-day  mortality  was  high,  25%  in  the  TAE
ohort  and  30.4%  in  the  surgery  cohort,  yet  these  mortality
ates  were  not  statistically  different.  The  majority  of  deaths
n  both  cohorts  were  from  nonbleeding  related  causes.  In
he  TAE  group,  there  were  signiﬁcantly  fewer  postprocedure
omplications,  and  no  procedure-induced  ischemic  events.
he  rebleeding  rate  noted  with  TAE  (34.4%)  was  not  different
rom  what  has  been  reported  elsewhere  in  the  literature.
ther  measured  patient  outcomes  including  total  length
f  hospital  stay,  length  of  hospital  stay  postprocedure,
nd  units  of  blood  transfused  were  no  different  between
he  TAE  and  surgery  groups.  These  results  are  promising,
nd  we  are  eagerly  awaiting  results  of  the  randomized
ontrolled  trial  from  the  Hong  Kong  team  (NCT00766961)
71],  which  is  currently  recruiting  to  prove  the  beneﬁts
f  TAE.
rophylactic embolization in high-risk peptic
lcer bleeding
ne  of  the  major  challenges  in  peptic  ulcer  bleeding  is
ebleeding  which  is  associated  with  up  to  a  ﬁve-fold  increase
n  mortality.  Recently,  Laursen  et  al.  [72]  examined  if
upplementary  transcatheter  arterial  embolization  (STAE)
erformed  after  achieved  endoscopic  hemostasis  improves
utcome  in  patients  with  high-risk  ulcers.  The  study  was
esigned  as  a  non-blinded,  parallel  group,  randomized  con-
rolled  trial  and  performed  in  a  university  hospital  setting.
atients  admitted  with  peptic  ulcer  bleeding  from  Forrest
a—IIb  ulcers  controlled  by  endoscopic  therapy  were  ran-
omized  (1:1  ratio)  to  STAE  of  the  bleeding  artery  within  24  h
r  continued  standard  treatment.  Randomization  was  strat-
ﬁed  according  to  stigmata  of  hemorrhage.  Patients  were
ollowed  for  30  days.  Primary  outcome  was  a  composite  end-
oint  where  patients  were  classiﬁed  into  ﬁve  groups  based
n  transfusion  requirement,  development  of  rebleeding,
eed  of  hemostatic  intervention  and  mortality.  Secondary
utcomes  were  rebleeding,  number  of  blood  transfusions
eceived,  duration  of  admission  and  mortality.  Totally  105
atients  were  included.  Of  the  49  patients  allocated  to
TAE  31  underwent  successful  STAE.  There  was  no  difference
n  composite  endpoint.  Two  versus  eight  patients  re-bled
n  the  STAE  and  control  group,  respectively.  After  adjust-
ent  for  possible  imbalances  a  strong  trend  was  noted
etween  STAE  and  rate  of  rebleeding  (P  =  0.079).  The  authors
oncluded  that  STAE  is  potentially  useful  for  preventingR.  Loffroy  et  al.
ebleeding  in  high-risk  peptic  ulcer  bleeding.  STAE  can  safely
e  performed  in  selected  cases  with  high  risk  of  rebleed-
ng.  Further  studies  are  needed  in  order  to  conﬁrm  these
ndings.
onclusion
assive  bleeding  from  the  upper  tract  remains  a  challenge.
 multidisciplinary  team  of  skilled  endoscopists,  intensive
are  specialists,  experienced  upper  gastrointestinal  sur-
eons,  and  interventional  radiologists  all  have  a  role  to  play.
he  past  three  decades  have  seen  enormous  advances  in
ndovascular  device  development  and  treatment  of  a  wide
ariety  of  hemorrhagic  conditions.  The  safety  and  efﬁcacy
f  TAE  for  the  treatment  of  life-threatening  acute  nonva-
iceal  UGIB  is  now  widely  accepted  and  is  considered  the
old  standard  for  endoscopy-refractory  patients.
Take-home  messages
• Gastroduodenal  peptic  ulcer  disease  is  the
most  common  cause  of  acute  nonvariceal  upper
gastrointestinal  bleeding.
• Transcatheter  arterial  embolization  has  become  the
ﬁrst-line  treatment  when  endoscopic  treatment  fails
to  control  acute  arterial  bleeding  from  the  upper
gastrointestinal  tract.
• Cyanoacrylate  glue  should  probably  be  used  more
often  in  such  a  setting,  especially  in  patients  with
coagulopathy,  because  it  provides  a  better  and  faster
hemostasis  and  does  not  cause  ischemia  in  well-
trained  hands.
• Most  groups  have  adopted  a  policy  to  perform
blind  embolization  on  the  basis  of  endoscopic
ﬁndings  in  situations  that  no  extravasation  is  seen
angiographically.
• Every  effort  should  be  made  to  correct  coagulopathy
before,  during,  and  after  intervention  because
among  clinical  predictors  of  rebleeding,
coagulopathy  has  been  shown  to  adversely  affect
the  success  rate  for  embolotherapy.
• Transcatheter  arterial  embolization  is  potentially
useful  even  for  preventing  rebleeding  in  high-risk
peptic  ulcer  bleeding.
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